The 13th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-13) will be held from October 14–16, 2026, in Palm Springs, California, USA, at the Renaissance Palm Springs Hotel & Conference Center, a premier venue located in the heart of downtown Palm Springs. Surrounded by the scenic San Jacinto Mountains, the area offers rich cultural experiences with historic landmarks, museums, gardens, and exceptional dining.

The Welcome Reception will take place on Tuesday, October 13, at the Renaissance Palm Springs Hotel. Opening Ceremonies will be hosted on Wednesday, October 14, at the inspiring Palm Springs Art Museum, while the Closing Ceremonies will be held on Friday, October 16, at the Westin Rancho Mirage. These venues provide a unique backdrop celebrating mid-century modern architecture, history, and culture, and will also host the Jan Gosta Waldenstrom, Robert A. Kyle, and Peter S. Bing Humanitarian Awards. The workshop will be co-chaired by Dr. Ranjana Advani (Stanford Medicine), Dr. Prashant Kapoor (Mayo Clinic), and Dr. Stephen Ansell (Mayo Clinic).

On Thursday, October 15, IWWM-13 will continue its commitment to advancing WM research through the Junior Investigator Poster Presentation and Young Investigator Awards. The top eight abstracts will be featured in a dedicated plenary session. Thanks to the generosity of the International Waldenstrom’s Macroglobulinemia Foundation (IWMF), the top 20 Young Investigator Award recipients will receive coverage for registration, travel, and lodging. Abstract submissions open March 2, 2026, and close July 17, 2026.

Building on the success of IWWM-12, which featured 23 sessions and over 90 presentations, IWWM-13 will deliver a robust scientific program addressing cutting-edge, patient-focused topics, including:

• Prognostic and therapeutic applications of genomic alterations (MYD88, CXCR4, TP53, 6q del, 17p del)
• Integration of newly recognized WM molecular entities (BCL, PCL) in therapy selection and drug development
• Early intervention strategies for high-risk smoldering WM
• Novel signal inhibitors and degraders targeting MYD88, CXCR4, BTK, HCK, IRAK1/4, and BCL2
• Combination therapies with BTK and BCL2 inhibitors
• Cellular therapies including T-cell engagers and CAR T-cells
• Clinical trial outcomes for high-risk WM patients and ongoing WM trials

The workshop’s leadership includes globally recognized experts who will shape the scientific agenda, oversee abstract selection, and lead consensus panels on clinical management.

Since its inception in 2000, IWWM has grown to include investigators from over 35 countries and has contributed to more than 8,000 publications in leading journals such as NEJM, Blood, Lancet, Nature, and Journal of Clinical Oncology. The mission remains clear: to advance understanding, diagnosis, treatment, and prevention of WM through research, education, and collaboration—ultimately striving for a cure.

We look forward to welcoming you to Palm Springs for IWWM-13 in 2026!